Shengda Bio-Pharm announced that the closing price of the company's stock on July 1, 2, and 3 in 2024 exceeded the deviation threshold by more than 20%, which is considered as abnormal stock trading according to the relevant provisions of the Shanghai Stock Exchange Trading Rules. After a company self-inspection and consulting with the controlling shareholder Zhejiang Shengda Group Co., Ltd. and the actual controller Hong Ainu, it is confirmed that there is no other major information that should be disclosed but has not been disclosed as of the date of this announcement. The net income belonging to the shareholders of the listed company achieved in 2023 is -54.06 million yuan; in the first quarter of 2024, the net income belonging to the shareholders of the listed company was 3.81 million yuan, an increase of 9.22% compared with the same period of the previous year.
两连板圣达生物：公司日常经营活动正常 不存在应披露而未披露的重大信息
Zhejiang Shengda Bio-Pharm, with two consecutive trading limit-up days, stated that the company's daily operations are normal and there is no significant information that should be disclosed but has not been disclosed.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.